94 related articles for article (PubMed ID: 26072317)
1. Tocilizumab for intestinal amyloidosis complicated by multi-centric Castleman's disease.
Tamura T; Tamura S; Tanaka H; Ohagi Y; Taniguchi F; Yamanishi H; Kohara T; Kimura R; Kurihara T; Ozaki T; Nakano Y; Fujimoto T
Clin Res Hepatol Gastroenterol; 2015 Dec; 39(6):e79-81. PubMed ID: 26072317
[No Abstract] [Full Text] [Related]
2. Multidisciplinary approach to the treatment of cardiac AA amyloidosis and aortic stenosis due to Castleman's disease: a hybrid therapy with tocilizumab and aortic valve replacement.
Shirakawa K; Egashira T; Ieda M; Kawaguchi S; Okamoto K; Kudo M; Yokoyama K; Tsuruta H; Murata M; Mikami S; Anzai A; Hayashida K; Kohno T; Maekawa Y; Sano M; Yozu R; Fukuda K
Int J Cardiol; 2014 May; 173(2):e9-e11. PubMed ID: 24681024
[No Abstract] [Full Text] [Related]
3. Successful use of tocilizumab in a case of multicentric Castleman's disease and end-stage renal disease.
Nagai K; Ueda A; Yamagata K
Ther Apher Dial; 2014 Apr; 18(2):210-1. PubMed ID: 24571441
[No Abstract] [Full Text] [Related]
4. A case of multicentric Castleman's disease associated with advanced systemic amyloidosis treated with chemotherapy and anti-CD20 monoclonal antibody.
Gholam D; Vantelon JM; Al-Jijakli A; Bourhis JH
Ann Hematol; 2003 Dec; 82(12):766-8. PubMed ID: 12898190
[TBL] [Abstract][Full Text] [Related]
5. Multicentric Castleman's disease complicated by secondary renal amyloidosis.
Leung KT; Wong KM; Choi KS; Chau KF; Li CS
Nephrology (Carlton); 2004 Dec; 9(6):392-3. PubMed ID: 15663642
[No Abstract] [Full Text] [Related]
6. [Castleman's disease and amyloidosis].
Olivares Martín J; Rivera Hernández F
Med Clin (Barc); 1990 Jun; 95(3):119. PubMed ID: 2250524
[No Abstract] [Full Text] [Related]
7. Good medium-term efficacy of tocilizumab in DMARD and anti-TNF-α therapy resistant reactive amyloidosis.
Hakala M; Immonen K; Korpela M; Vasala M; Kauppi MJ
Ann Rheum Dis; 2013 Mar; 72(3):464-5. PubMed ID: 23148310
[No Abstract] [Full Text] [Related]
8. Long-term tocilizumab efficacy in a patient with psoriatic arthritis and AA amyloidosis.
Dinoia L; Lopalco G; Cantarini L; Gesualdo L; Rossini M; Iannone F
Clin Exp Rheumatol; 2017; 35(1):170-171. PubMed ID: 27908297
[No Abstract] [Full Text] [Related]
9. Localised plasma-cell type Castleman's disease and AA-amyloidosis cured by resection. A case report and review of the literature.
Verbrugghe W; Maes BD; Knockaert DC
Acta Clin Belg; 2005; 60(1):22-7. PubMed ID: 15981701
[TBL] [Abstract][Full Text] [Related]
10. Tocilizumab treatment for nephrotic syndrome due to amyloidosis in Behcet's disease.
Redondo-Pachón MD; Enríquez R; Sirvent AE; Andrada E; Noguera-Pons R; Millán I; Amorós F
Ren Fail; 2013; 35(4):547-50. PubMed ID: 23472940
[TBL] [Abstract][Full Text] [Related]
11. [Castleman's disease in the pelvic cavity].
Kawamura N; Hayashi T; Abe T; Nakayama J; Mori N; Sekii K; Yoshioka T; Itatani H
Hinyokika Kiyo; 2007 Feb; 53(2):141-4. PubMed ID: 17352168
[TBL] [Abstract][Full Text] [Related]
12. Long-term remission in idiopathic Castleman's disease with tocilizumab followed by consolidation with high-dose melphalan--two case studies.
Jerkeman M; Lindén O
Eur J Haematol; 2016 May; 96(5):541-3. PubMed ID: 26256458
[TBL] [Abstract][Full Text] [Related]
13. Successful tocilizumab treatment in a patient with human herpesvirus 8-positive and human immunodeficiency virus-negative multicentric Castleman's disease of plasma cell type nonresponsive to rituximab-CVP therapy.
Műzes G; Sipos F; Csomor J; Sréter L
APMIS; 2013 Jul; 121(7):668-74. PubMed ID: 23163599
[TBL] [Abstract][Full Text] [Related]
14. Systemic connective tissue disease complicated by Castleman's disease: report of a case and review of the literature.
De Marchi G; De Vita S; Fabris M; Scott CA; Ferraccioli G
Haematologica; 2004 Apr; 89(4):ECR03. PubMed ID: 15075095
[TBL] [Abstract][Full Text] [Related]
15. HIV-associated Castleman's disease: from case reports to evidence.
Bazeos A; Powles T; Stebbing J
J HIV Ther; 2007 Sep; 12(3):61-2. PubMed ID: 17962792
[No Abstract] [Full Text] [Related]
16. AA amyloidosis in a polyarteritis nodosa patient treated with tocilizumab.
Hočevar A; Lestan B; Šemrl SS; Lakota K; Kojc N; Potočnik N; Tomšič M
Amyloid; 2013 Dec; 20(4):275-6. PubMed ID: 24106820
[TBL] [Abstract][Full Text] [Related]
17. Remissions of different quality following rituximab, tocilizumab and rituximab, and allogeneic stem cell transplantation in a patient with severe idiopathic multicentric Castleman's disease.
Angenendt L; Kerkhoff A; Wiebe S; Mikesch JH; Rudat A; Wötzel F; Wenning C; Schliemann C; Kessler T; Schäfers M; Wardelmann E; Stelljes M; Berdel WE
Ann Hematol; 2015 Jul; 94(7):1241-3. PubMed ID: 25791243
[No Abstract] [Full Text] [Related]
18. Immunotherapeutic implication of IL-6 blockade.
Tanaka T; Kishimoto T
Immunotherapy; 2012 Jan; 4(1):87-105. PubMed ID: 22150003
[TBL] [Abstract][Full Text] [Related]
19. [Multicentric Castleman's disease (MCD): recent knowledge of its pathogenesis].
Higashibara M; Horie R; Yoneyama A; Mori S
Rinsho Ketsueki; 1992 Nov; 33(11):1649-60. PubMed ID: 1469779
[No Abstract] [Full Text] [Related]
20. Localized Castleman's disease associated with systemic AA amyloidosis. Regression of amyloid deposits after tumor removal.
Androulaki A; Giaslakiotis K; Giakoumi X; Aessopos A; Lazaris AC
Ann Hematol; 2007 Jan; 86(1):55-7. PubMed ID: 17001479
[No Abstract] [Full Text] [Related]
[Next] [New Search]
